Lung cancer biopsy dislodges tumor cells into circulating blood

Sawabata, Noriyoshi; Kitamura, Tomotaka; Nitta, Yuko; Taketa, Tomoyo; Ohno, Takeshi; Fukumori, Tatsuya; Hyakutake, Takeru; Nakamura, Takahito

doi:10.20517/2394-4722.2016.67

Cited by 4 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this respect, a recent study analyzed CTC in peripheral vein blood samples obtained before and after lung tumor biopsy using flexible fiber-topic bronchoscopy. In 2/6 patients, CTC were absent before bronchoscopy but they were detected after lung biopsy (13). In early lung cancer, CTC can be detected in the pulmonary vein (PV) blood in addition to the peripheral blood.…”

Section: Detection and Prognostic Value Of Ctc In Early Nsclcmentioning

confidence: 99%

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer

Gallo

Luca

Maiello

et al. 2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Several different studies have addressed the role of the circulating tumor cells (CTC) in nonsmall-cell lung cancer (NSCLC). In particular, the potential of CTC analysis in the early diagnosis of NSCLC and in the prediction of the outcome of patients with early and advanced NSCLC have been explored. A major limit of these studies is that they used different techniques for CTC isolation and enumeration, they employed different thresholds to discriminate between high-and low-risk patients, and they enrolled heterogeneous and often small cohort of patients. Nevertheless, the results of many studies are concordant in indicating a correlation between high CTC count and poor prognosis in both early and advanced NSCLC. The reduction of CTC number following treatment might also represent an important indicator of sensitivity to therapy in patients with metastatic disease. Preliminary data also suggest the potential for CTC analysis in the early diagnosis of NSCLC in high-risk individuals. However, these findings need to be confirmed in large prospective trials in order to be transferred to the clinical practice.The molecular profiling of single CTC in NSCLC might provide important information on tumor biology and on the mechanisms involved in tumor dissemination and in acquired resistance to targeted therapies. In this respect, xenografts derived from CTC might represent a valuable tool to investigate these phenomena and to develop novel therapeutic strategies.

show abstract

Section: Detection and Prognostic Value Of Ctc In Early Nsclcmentioning

confidence: 99%

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer

Gallo

Luca

Maiello

et al. 2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

show abstract

“…Aside from VFL, other modalities can also cause the release of CTCs. Bronchoscopic biopsies cause CTC release [19]. In addition, preoperative bronchoscopy with uoroscopic imaging has been reported to be associated with a high incidence of recurrence [20].…”

Section: Discussionmentioning

confidence: 99%

Does Vein-first Lobectomy Control Postoperative Circulating Tumor Cells in Lung Cancer?: a Retrospective Observational Study

Sawabata

Nakane

Yoshikawa

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Vein-first dissecting lobectomy in lung cancer surgery is speculated to limit the amount of circulating tumor cells. We aimed to assess the clinical significance and prognostic impact of Vein-first dissecting lobectomy according to changes in circulating tumor cell status throughout the perioperative period.Methods: Among patients with pulmonary nodule who underwent surgery, we extracted and evaluated patients who underwent lobectomy for lung cancer and had underwent circulating tumor cell testing before and immediately after the completion of lobectomy. The primary evaluation item was the detection rate of postoperative circulating tumor cell according to the sequence of pulmonary vessel processing. The secondary evaluation items were the 2-year recurrence-free survival and overall survival rates according to the status of Vein-first dissecting lobectomy and postoperative circulating tumor cell. Results: Between June 2014 and June 2018, 302 patients with pulmonary nodule underwent surgery, among them we selected 86 patients who underwent lobectomy for lung cancer and had circulating tumor cell testing done before and immediately after the completion of lobectomy. The circulating tumor cell identification rates in the postoperative period were 54.4% (37/68) and 66.7% (12/18) (p=0.8) in vein-first dissecting lobectomy group and no-vein-first dissecting lobectomy group, respectively. The mean postoperative circulating tumor cell count was not significantly different between the vein-first dissecting lobectomy and no-vein-first dissecting lobectomy groups (3.0 ± 3.6 vs 3.2 ± 5.0, p=0.8). The 2-year recurrence-free survival and overall survival rates were also not significantly different. However, the presence of circulating tumor cell after surgery was a predictor of recurrence.Conclusions: Although the detection of circulating tumor cell after surgery is a predictor of cancer recurrence, no significant difference was observed in the status of postoperative circulating tumor cell s between vein-first dissecting lobectomy and no- vein-first dissecting lobectomy groups in lung cancer surgery.

show abstract

“…In brief, BFS was an independent indicator of recurrence, but successful diagnosis by TBB, which is a surrogate marker of disruption of the main tumor, was not an indicator of recurrence. It should be noted that there is evidence of lung cancer biopsy dislodging tumor cells into the circulating blood (4).…”

Section: Discussionmentioning

confidence: 99%

“…This has been shown both in ex vivo resected lung, and through tumor cell dislodgement by TBB resulting in circulating tumor cells (4). It should, also, be noted that inflammation has been suggested to play a key role in lung carcinogenesis (5) and that both chronic inflammation and acute inflammation is associated with tumorigenesis (6,7).…”

mentioning

confidence: 93%

Clinical Implications of Transbronchial Biopsy for Surgically-resected Non-small Cell Lung Cancer

Yasukawa

Sawabata

Kawaguchi

et al. 2018

View full text Add to dashboard Cite

show abstract

Lung cancer biopsy dislodges tumor cells into circulating blood

Cited by 4 publications

References 27 publications

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer

Does Vein-first Lobectomy Control Postoperative Circulating Tumor Cells in Lung Cancer?: a Retrospective Observational Study

Clinical Implications of Transbronchial Biopsy for Surgically-resected Non-small Cell Lung Cancer

Contact Info

Product

Resources

About